



ESMO Advanced Course on ADC Development, Therapeutic Applications and Research: Breast, Gynaecological and Gastrointestinal Cancers

PROGRAMME

**ESMO
ADVANCED COURSE**

**SINGAPORE
11-12 OCTOBER 2024**

Co-Chairs

Elizabeth Smyth, United Kingdom
David S. P. Tan, Singapore

ESMO ADVANCED COURSE PROGRAMME

ADC DEVELOPMENT, THERAPEUTIC APPLICATIONS AND RESEARCH: BREAST, GYNAECOLOGICAL AND GI CANCERS

Singapore

11-12 October 2024

CO-CHAIRS Elizabeth Smyth, United Kingdom
David S. P. Tan, Singapore

SPEAKERS Tom W.-W. Chen, Taiwan
Rebecca A. Dent, Singapore
Elisa Fontana, United Kingdom
Joline Lim, Singapore
Josh C. C. Lin, Taiwan
Brigette Ma, Hong Kong SAR, China
Caterina Marchiò, Italy

LEARNING OBJECTIVES

- To provide insights on ADCs drug development
- To explain mechanism of action of the most common ADCs used in clinical practice
- To highlight the integration of ADCs in current clinical practice guidelines across pathologies
- To provide guidance on management of toxicities of ADCs

ACCREDITATION

The programme of this event has been accredited with **8 ESMO-MORA category 1 points**.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to [esmo.org](https://www.esmo.org).

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4,
6900 Lugano, Switzerland
Email: courses@esmo.org
www.esmo.org



Friday, 11 October 2024

09:00-09:10 **Welcome and introduction**

10' Welcome and Learning Objectives
Elizabeth Smyth, UK and David S. P. Tan, SG

09:10-10:15 **Session 1 – ADC Development and pharmacodynamics – Part I** Chair: Elizabeth Smyth, UK

20' ADC development: What are the considerations in early phase trials?
Josh C. C. Lin, TW

20' Mechanisms of action and resistance: ADC internalization and cleavage and mechanisms of resistance
Tom W.-W. Chen, TW

25' Q&A

10:15-10:45 Coffee break

10:45-15:15 **Workshop sessions**

Three parallel workshop sessions with 20 delegates in each group (delegates will attend all 3 sessions on a rotational basis)

15' Introduction based on clinical cases presented by speakers
40' Discussion
5' Break

Workshop 1 ADC trials in breast cancer
60' Joline Lim, SG

Workshop 2 ADC trials in gastrointestinal cancers
60' Elizabeth Smyth, UK

Workshop 3 ADC trials in gynaecological cancer
60' David S. P. Tan, SG

12:45-13:45 Lunch

13:45-14:45 **Workshops continuation**

14:45-15:15 **Feedback on the workshops from each group**

15:15-15:45 Coffee break

15:45-16:15 **Session 2 – ADC Development and pharmacodynamics – Part II**

Chair: David S. P. Tan, SG

20' Toxicity: Prediction, identification and treatment
Rebecca A. Dent, SG

10' Q&A

19:00 *Networking dinner*

Saturday, 12 October 2024

09:00-10:25 **Session 3 – Target assessment, rational combos and future gazing – Part I**

Chair: David S. P. Tan, SG

20' Considerations from pathology: Biomarker selection, on-target, off-tumour expression, off-target toxicities
Caterina Marchiò, IT

35' Developments in ADC constructs including: Bispecific ADCs, cytokine, peptide-based conjugates
Elisa Fontana, UK

30' Q&A

10:25-10:55 *Coffee break*

10:55-11:35 **Session 4 – Target assessment, rational combos and future gazing – Part II**

Chair: Elizabeth Smyth, UK

20' How to develop rationale combinations and sequencing
Brigette Ma, HK SAR, CN

20' Q&A

11:35-11:50 **Synthesis and wrap-up**

Elizabeth Smyth, UK and David S. P. Tan, SG

11:50-13:00 *Lunch*